Suchergebnisse
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago
Arvinas Q2 Earnings Call Highlights
Key Points
- Interested in Arvinas, Inc.? Here are five stocks we like better.
- Arvinas is shifting resources to early-stage oncology and neurology programs after the FDA approved VEPPANU, the
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas, Inc. (ARVN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates
AT&T Inc..
WKN: A0HL9Z / Symbol: T / Name: AT&T / Aktie / Telekommunikationsdienstleistungen / Large Cap /
Accuray Inc.
WKN: A0MKWM / Symbol: ARAY / Name: Accuray / Aktie / Ausrüstung & Versorgung / Small Cap /
AZZ Inc.
WKN: 863132 / Symbol: AZZ / Name: AZZ / Aktie / Maschinen, Ausrüstung & Teile / Small Cap /
ASGN Inc.
WKN: A2JG99 / Symbol: ASGN / Name: ASGN / Aktie / Kommerzielle Dienstleistungen / Mid Cap /
AAON Inc.
WKN: 894255 / Name: AAON / Aktie / Maschinen, Ausrüstung & Teile / Mid Cap /
Ardelyx Inc.
WKN: A116X0 / Name: Ardelyx / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Arch Coal Inc
WKN: A2AS8M / Symbol: ARCH / Name: Arch Coal / Aktie / Kohle / Small Cap /
Arcosa Inc
WKN: A2N62P / Symbol: ACA / Name: Arcosa / Aktie / Bau & Bautechnik / Small Cap /
